DNA-dependent protein kinase (DNA-PK) and poly (ADP-ribose) polymerase-1 (PARP-1) participate in nonhomologous end joining and base excision repair, respectively, and are key determinants of radio-and chemo-resistance. Both PARP-1 and DNA-PK have been identified as therapeutic targets for anticancer drug development. Here we investigate the effects of specific inhibitors on enzyme activities and DNA double-strand break (DSB) repair. The enzyme activities were investigated using purified enzymes and in permeabilized cells. Inhibition, or loss of activity, was compared using potent inhibitors of DNA-PK (NU7026) and PARP-1 (AG14361), and cell lines proficient or deficient for DNA-PK or PARP-1. Inactive DNA-PK suppressed the activity of PARP-1 and vice versa. This was not the consequence of simple substrate competition, since DNA ends were provided in excess. The inhibitory effect of DNA-PK on PARP activity was confirmed in permeabilized cells. Both inhibitors prevented ionizing radiation-induced DSB repair, but only AG14361 prevented single-strand break repair. An increase in DSB levels caused by inhibition of PARP-1 was shown to be caused by a decrease in DSB repair, and not by the formation of additional DSBs. These data point to combined inhibition of PARP-1 and DNA-PK as a powerful strategy for tumor radiosensitization.
Introduction
Enzyme-mediated repair of DNA double-strand breaks (DNA DSBs) is a major mechanism of resistance to radiotherapy, and inhibition of DNA DSB repair is thus a strategy for radiopotentiation. The DNA-dependent protein kinase (DNA-PK) and poly(ADP-ribose) polymerase-1 (PARP-1) are DNA strand break-activated enzymes, and key components of DNA damage recognition, repair and signalling pathways. The DNA-PK holoenzyme comprises a heterodimer of B70 and B80 kDa polypeptides, known as Ku, which binds to DNA strand breaks, recruiting and activating the 470 kDa catalytic subunit, termed DNA-PKcs . DNA-PK, together with the XRCC4/DNA ligase IV complex and the recently identified cofactor Artemis, is specifically required for nonhomologous end joining (NHEJ), with about 80% of DNA DSBs repaired by this pathway (Jeggo, 1997; DiBiase et al., 2000; Pannicke et al., 2002) . PARP-1 plays an important role in chromatin remodelling following DNA damage, and is a component of the base excision repair (BER) complex required for DNA single-strand break (DNA SSB) repair (de Murcia and Menissier de Murcia, 1994; Smith, 2001 ). However, we have recently reported that a PARP-1 inhibitor (NU1025) also inhibits DNA DSB repair in cells exposed to ionizing radiation (IR), and this may contribute to the cytotoxic mechanism (Boulton et al., 1999) .
A number of publications suggest interaction between DNA-PK and PARP-1. Both enzymes have high affinities for binding to DNA DSBs (Benjamin and Gill, 1980; D'Silva et al., 1999) . Automodification (phosphorylation of DNA-PKcs and poly(ADP-ribosylation) of PARP-1) is a prerequisite for the release of these enzymes from DNA ends (Smulson et al., 1998; Merkle et al., 2002) . Heteromodification and modulation of enzyme activity in vitro, viz, poly(ADP-ribosylation) of DNA-PK by PARP-1, and phosphorylation of PARP-1 by DNA-PK have also been demonstrated, suggesting reciprocal regulation of enzyme activity (Ruscetti et al., 1998; Ariumi et al., 1999) . DNA-PKcs contains a peptide motif which binds free ADP-ribose polymers with high specificity (Pleschke et al., 2000) . PARP-1 and DNA-PK bind synergistically to matrix attachment regions, and Ku autoantigen forms a complex with PARP-1 in the absence of DNA, indicating an intimate association of the two enzymes (Galande and Kohwi-Shigematsu, 1999) .
The clinical potential of DNA repair inhibitors has led to the development of diverse classes of potent PARP-1 inhibitors (Tentori et al., 2002) . The synthesis of the novel tricyclic benzamidizole, AG14361, 1-(4-dimethylaminomethyl-phenyl)-8,9-dihydro-7H-2,7, 9a-benzo[cd]azulen-6-one, has recently been described, and has been used in this study (Skalitzky et al., 2003) . The recently synthesized molecule NU7026, 2-(morpholin-4-yl)-benzo[h]chomen-4-one, is a specific inhibitor of DNA-PK. We have demonstrated that AG14361 and NU7026 act as potent radiosensitizers in both proliferating and quiescent cells, and increase steady-state levels of DNA DSBs in their respective enzyme-proficient, but not enzyme-deficient cell lines (Veuger et al., 2003) . Thus, the radiosensitizing effects of these inhibitors are attributable to their action as DNA repair inhibitors. The possible functional associations of the enzymes were revealed when NU7026 and AG14361 were used in combination.
The goal of this study was to investigate the interaction of DNA-PK and PARP-1 at DNA ends, using both purified enzymes and a permeabilized cell assay. Enzyme activity was modulated by the use of NU7026 or AG14361, and by inclusion or exclusion of enzyme substrates. Paired cell lines proficient or deficient in either DNA-PK or PARP-1 were also used to compare the effects of loss of enzyme as opposed to enzyme inactivation. A comparison of the loss, or inhibition, of the enzymes' activities on DNA DSB and SSB repair was also carried out.
Results
Inactive DNA-PK inhibits PARP-1 activity
The effect of AG14361 and NU7026 on purified PARP-1 activity was investigated ( Figure 1a ). As expected, PARP-1 activity was almost completely inhibited by AG14361, whereas NU7026 had no effect. Addition of an equimolar concentration of DNA-PK to the assay inhibited PARP-1 activity by 30%. Activation of DNA-PK by the addition of ATP reversed this PARP-1 inhibition, but the further inclusion of NU7026 restored the PARP-1 inhibition. In summary, whereas active DNA-PK did not modulate PARP-1 activity, the presence of inactive DNA-PK (by substrate deprivation or inhibition) caused significant PARP-1 inhibition. Increasing the molar ratios of DNA-PK to PARP-1 (Figure 1b ) resulted in a concentrationdependent inhibition of PARP-1 activity such that, with a molar ratio of 3 : 1 (DNA-PK : PARP-1), PARP-1 activity was inhibited by 495%. However, this inhibition was completely reversed by the inclusion of ATP as substrate for DNA-PK.
Inactive PARP-1 inhibits DNA-PK activity
The effect of the inhibitors on purified DNA-PK was also investigated (Figure 2a ). DNA-PK activity was inhibited by NU7026, whereas AG14361 had no effect. Addition of an equimolar concentration of PARP-1 inhibited DNA-PK activity by 82%, and again, similar to the effects of DNA-PK on PARP-1 activity, addition of the PARP-1 substrate, NAD þ , released the inhibition of DNA-PK activity, unless AG14361 was also included. Increasing the molar ratios of PARP-1 to DNA-PK resulted in a concentration-dependent inhibition of DNA-PK that was reversible by the inclusion of NAD þ ( Figure 2b ).
PARP-1 activity is inhibited by inactive DNA-PK in permeabilized cells
Cell lines proficient or deficient in either DNA-PK (V3YAC and V3) or PARP-1 (PARP-1 þ / þ and PARP-1 À/À ) were rendered nucleotide-permeable by digitonin treatment and used as a basis for a PARP-1 assay. PARP-1 activity was slightly, but significantly, different in the V3YAC and V3 cells (12977 pmol compared to 14972 pmol NAD/10 6 cells (P ¼ 0.06, Figure 3a and b). ATP (50 mM) stimulated PARP-1 activity (15072 pmol NAD/10 6 cells, P ¼ 0.02) in the V3YAC cells, but not in the V3 cells. As expected, AG14361 almost completely inhibited PARP-1 activity in both cell lines. In contrast, NU7026 reduced PARP-1 activity by 61% in the V3YAC cells, while having little or no effect in the V3 cells.
PARP-1 activity was present in the PARP-1 þ / þ cells, while the PARP-1 À/À cells retained a small, but significant residual activity (470.3 compared to 1327 3.8 pmol NAD/10 6 cells in the PARP-1 þ / þ cells) ( Figure  3c and d). This activity is probably attributable to PARP-2, which, together with PARP-1, has also been implicated in BER (Schreiber et al., 2002) . Not only did AG14361 completely inhibit PARP-1 activity in the PARP-1 þ / þ cells, but it also inhibited the residual activity in the PARP-1 À/À cells. Similarly, NU7026 reduced PARP activity in both cell lines, indicating that DNA-PK inhibition also modulates this second PARP activity.
In contrast to the observation that PARP activity in permeabilized cells was o5% of the total stimulatable activity in the absence of oligonucleotides, and abolished in the presence of AG14361, attempts to measure DNA-PK activity in oliigonucleotide-stimulated permeabilized cells were confounded by high levels of nonspecific kinase activity in DNA-PK-deficient or inhibited cells.
Modulation of DNA SSB and DSB levels by inhibition of PARP-1 and DNA-PK IR produces a complex array of lesions in the DNA, resulting in the production of SSBs and DSBs that are repaired by BER and NHEJ, respectively. IR-induced DNA SSBs and DSBs were measured 60 min post-IR in the V3YAC and V3 cells, by which time the majority of breaks had been rejoined in cells incubated in the absence of inhibitor(s). Figure 4 shows a comparison of DNA DSB and SSB repair. The presence of either AG14361 or NU7026 resulted in a substantial inhibition Effects of AG14361 and NU7026 on DNA DSB and SSB repair. Cells were pre-incubated7inhibitor(s) for 60 min, exposed to 75 GY IR (DSB assays) or 6 GY IR (SSB assays) and either harvested immediately and kept on ice, or post-incubated for 60 min before harvesting. Samples were then prepared for neutral (DSBs) or alkaline (SSBs) elution. Results are expressed as % repair and are the means of at least three independent experiments7s.e. (a) DSB and SSB repair in V3YAC cells; (b) DSB and SSB repair in V3 cells. Black bars, DSB levels; white bars, SSB levels of DSB repair in the V3YAC cells ( Figure 4a , filled bars). DSB repair was reduced in the DNA-PK deficient V3 cells compared to the V3YAC cells, and, while AG14361 reduced this repair further, NU7026 had no effect ( Figure 4b , filled bars). In marked contrast, whereas AG14361 inhibited SSB repair in both V3YAC and V3 cells, NU7026 had no effect in either cell line (Figure 4a and b, open bars). Furthermore, as would be predicted, SSB repair in the absence of inhibitors was equally effective in both the V3YAC and V3 cell lines. The production of DNA SSBs or DSBs was not caused by a direct effect of the inhibitors on the integrity of the DNA, as the elution profiles from cells exposed to the inhibitors alone were the same as untreated controls (data not shown). Increased DSB levels in cells exposed to IR in the presence of AG14361 could have resulted from formation and accumulation of additional DSBs as opposed to a direct inhibition of NHEJ. To differentiate between these two possible mechanisms, we used the xrs-6 cell line which lacks the Ku80 subunit of DNA-PK and is defective in NHEJ (Kemp et al., 1984) . We postulated that if inhibition of PARP-1 resulted in the production of additional DSBs, then DSB levels would increase in xrs-6 cells during incubation following exposure to IR. The results are shown in Figure 5 . To ensure that additional breaks would be measurable, xrs-6 cells were irradiated with 42 Gy compared to 75 Gy for parental CHO-K1 cells (compare break levels at time zero for CHO-K1 and xrs-6, Figure 5a and b). We have previously demonstrated a linear dose-response for DSB levels up to 80 Gy (results not shown). Whereas DSBs were almost completely rejoined by 120 min in CHO-K1 cells, rejoining was completely absent in the xrs-6 cells (compare Figure 5a and b) . As expected, DSB levels remained high at 120 min in the CHO-K1 cells incubated with AG14361, indicative either of an inhibition of DSB rejoining or an accumulation of additional DSBs post-IR (Figure 5a ). In the xrs-6 cells, AG14361 had no effect at all on DSB levels, which remained as high, but no higher, at 120 min compared to immediately post-IR (Figure 5b ). This result supports the conclusion that AG14361 inhibits NHEJ.
Discussion
We have used potent inhibitors of DNA-PK and PARP-1, substrate deprivation and cell lines proficient or deficient in the activities of these enzymes to investigate the interaction of the enzymes. The impact of the inhibitors alone and in combination on IR-induced DNA SSB and DSB levels was also investigated.
The activities of purified PARP-1 and DNA-PK were not affected by the presence of the other enzyme, as long as it was active. However, inactive DNA-PK inhibited PARP-1, and inactive PARP-1 inhibited DNA-PK, both in a concentration-dependent manner. Importantly, we demonstrated that NU7026 is not a direct inhibitor of PARP-1 and AG14361 is not a direct inhibitor of DNA-PK. In conclusion, inactive DNA-PK can inhibit PARP-1 and vice versa.
Similarly, in permeabilized cells, NU7026 or reduced ATP concentration inhibited PARP-1 activity in the DNA-PK-proficient cells (V3YAC, PARP-1 þ / þ and PARP-1 À/À ), but not the DNA-PK-deficient cells (V3). Although inhibition of DNA-PK inhibited PARP-1, as in the purified enzyme assay, absence of ATP had less impact. However, it is likely that at least some of the intracellular ATP is retained by protein binding, and hence is available for DNA-PK function. Although these in vitro experiments do not directly prove similar in vivo interactions, they suggest that the inhibition of one enzyme may compromise the activity of the other in intact cells.
D 'Silva et al. (1999) compared the apparent dissociation constants (K d app ) of purified PARP-1 and DNA-PK with different types of DNA strand interruptions. Surprisingly, despite its purported predominant role in BER, which produces only DNA SSBs, PARP-1 had a 3-4-fold higher affinity for blunt ends (K d app ¼ 116 pM) Figure 5 effect of AG14361 on DNA DSB repair following exposure to IR. Cells were pre-incubated7AG14361 for 60 min, exposed to 75 Gy (CHO-K1) or 42 Gy (xrs-6) and either harvested immediately and kept on ice, or post-incubated for 60 or 120 min before harvesting for neutral elution. Results are expressed as DNA DSB levels, and are the means of three independent experiments7s.e. (a) CHO-K1 cells; (b) xrs-6 cells compared to nicks and 3 0 single-base overhangs. The K d app of DNA-PK for blunt ends (1312 pM) was considerably higher than the PARP-1 value, indicating that when DNA-PK and PARP-1 are in competition for binding to a break it would be bound preferentially by PARP-1.
Our observation that inactive PARP-1 had a greater impact on DNA-PK activity than vice versa (82% compared to 30% inhibition) is consistent with the lower K d app value of PARP-1 compared to DNA-PK. However, in the experiments described here, the numbers of DNA ends were in 10-fold excess over the numbers of molecules of each enzyme, and therefore competition for DNA end binding should have been minimized. A possible explanation for these observations is that PARP-1 and Ku form a molecular complex in the absence of DNA (Galande and Kohwi-Shigematsu, 1999) . The location of Ku at DNA ends serves to recruit and activate DNA-PKcs. Thus, it may be envisaged that Ku, by forming a DNA-independent complex with PARP-1, may co-locate DNA-PKcs and PARP-1 to the same DNA ends, even in the presence of excess free ends. In further support of this model, it has recently been reported that the Werner's syndrome protein WRN forms a molecular complex with Ku70/80 and PARP-1, and that PARP-1 poly(ADP-ribosyl)ates Ku70/80 in vitro, reducing its DNA-binding activity, and weakening its ability to stimulate exonuclease activity of WRN (Li et al., 2004) . The relative affinities of PARP-1 and Ku to each other and to DNA ends are not known, and this area merits further investigation.
Whereas AG14361 inhibited DNA SSB repair, NU7026 had no effect. Since DNA-PK is neither bound nor activated by nicks (Gottlieb and Jackson, 1993) , and does not participate in BER, the lack of an effect of NU7026 on DNA SSB repair was predictable. In contrast, both AG14361 and NU7026 inhibited DNA DSB repair. In agreement with DiBiase et al. (2000) , when DNA-PKcs was absent or inhibited, DNA DSB repair was partially inhibited. Similarly, PARP-1 inhibition reduced DSB repair, consistent with the impaired DSB repair in PARP-1 À/À cells (Veuger et al., 2003) . Importantly, AG14361 was able to further inhibit repair in the DNA-PK-deficient V3 cells. This indicates that although inhibition of PARP-1 may retard DNA DSB repair indirectly by inhibiting DNA-PK (as suggested by the enzyme assays), it also possesses independent functions in DSB repair. It was noteworthy that AG14361 was as effective at inhibiting DNA DSB repair as SSB repair. When the inhibitors were used in combination, DNA DSB repair was almost completely inhibited.
These experiments do not, however, actually distinguish between inhibition of DSB rejoining, as opposed to accumulation of additional DSBs post-IR. IRinduced clustered damage involves near-neighbour base oxidation and hydrolysis of the phosphodiester backbone on opposite DNA strands (Ward, 1988) . Inhibition of PARP-1 may result in the longer-lived DNA SSBs converting to DNA DSBs. In order to distinguish between these alternative mechanisms, the effect of AG14361 on IR-induced DSB levels in xrs-6 cells was investigated. In our hands, this cell line was completely defective in NHEJ at early times post-IR (p2 h). Hence, it was possible to show that no further breaks accumulated post-IR in the presence of AG14361, demonstrating unequivocally that AG14361 acts as an inhibitor of NHEJ.
The high affinity of PARP-1 for binding to DNA DSBs, first described by Benjamin and Gill (1980) , and recently confirmed by D' Silva et al. (1999) , has lacked a functional interpretation. The data presented here, together with our previous demonstration that net DSB levels were increased in irradiated PARP-1 À/À compared to PARP-1 þ / þ MEFs (Veuger et al., 2003) , suggest that PARP-1 function is implicated in NHEJ. However, it is still possible that only inhibited PARP-1 retards NHEJ, while absence of PARP-1 may lead to the generation of additional DSBs, as described above. Additionally, we cannot exclude the possibility that the PARP-1 À/À MEFs, which are disrupted in exon 4 (Menissier de Murcia et al., 1997), may produce a dominantly acting DNA-binding fragment which could interfere with NHEJ. This is exemplified by Rudat et al. (2001) , who demonstrated that overexpression of the DNA-binding domain of PARP-1 inhibited the fast component (i.e. NHEJ) of DNA DSB repair. Recent reports have implicated PARP-1 function in NHEJ and HRR (Schultz et al., 2003; Susse et al., 2004) . However, another report suggests that lack of PARP-1 affects neither repair pathway (Yang et al., 2004) . Further experiments are required to elucidate the effects of inhibited PARP-1 compared to absence of PARP-1 (e.g. by using small interfering RNA) in both BER and NHEJ.
The dissociation kinetics of PARP-1 and DNA-PK from DNA ends in vivo will be changed dramatically by the presence of potent inhibitors. PARP-1 and DNA-PK undergo automodification when activated by DNA strand breaks, and this reaction is essential to release PARP-1 and DNA-PKcs from the DNA ends. Thus inhibited DNA-PK and PARP-1 will remain tethered to the DNA ends. As an example, wortmannin (also a DNA-PK inhibitor, Izzard et al., 1999) blocks DNA-PK at DNA ends, and prevents their processing by DNA polymerization, degradation, or ligation (Calsou et al., 1999) . Satoh and Lindahl (1992) also demonstrated that inactive PARP-1 sequestered DNA ends and prevented repair in a cell-free assay. Similarly, NU7026 and AG14361 will block DNA-PK and PARP-1, respectively, at DNA ends. As well as interfering with the access and activation of the other enzyme, these proteinbound DNA termini could hinder assembly of the enzyme complexes required for the successful execution of NHEJ and HRR.
The current interest in DNA-PK as a therapeutic target is demonstrated by the various strategies that have been deployed to selectively deplete or inhibit DNA-PK function (e.g. Kim et al., 2002; Omori et al., 2002; Peng et al., 2002; Sak et al., 2002) . A PARP-1 inhibitor has recently entered Phase 1 clinical trials under the auspices of Cancer Research UK. Here, we have shown in cell-free assays that inhibition of PARP-1 attenuates the activity of DNA-PK and vice versa, and that these inhibitors retard NHEJ in intact cells. Thus, the combined inhibition of PARP-1 and DNA-PK could prove a powerful strategy for tumour radiosensitization.
Materials and methods

Oligonucleotide and enzymes
Purified human PARP-1 was a gift from Pfizer GRD, CA, USA. Purified DNA-PK was supplied by KuDOS Pharmaceuticals, Cambridge. Note that the term DNA-PK, as used in the text, refers to the holoenzyme, comprising equimolar ratios of DNA-PKcs, Ku70 and Ku80. A 30 bp blunt-ended doublestranded DNA oligonucleotide (5 0 -ACTTGATTAGTTACG-TAACGTTATGATTGA-3 0 ) was used as the activating cofactor for both DNA-PK and PARP-1. This oligonucleotide was present in all the purified enzyme and permeabilized cell assays described below, and both DNA-PK and PARP-1 activities were very low or undetectable in its absence. The number of DNA ends in all the assays was at least 10-fold greater than the number of enzyme molecules.
Drugs
NU7026 was synthesized by the Department of Chemistry, University of Newcastle upon Tyne. AG14361 was synthesized by Pfizer GRD, CA (Skalitzky et al., 2003) . NU7026 and AG14361 were dissolved in anhydrous dimethyl sulphoxide (DMSO) at stock concentrations of 5 and 10 mM, respectively, and stored at À201C. Drugs (alone or in combination) were added to enzyme assays and cell cultures so that the final DMSO concentrations were kept constant at 1% (v/v).
Evaluation of enzyme inhibition
AG14361 is a potent competitive inhibitor of PARP-1 with a K i value o5 nM (Skalitzky et al., 2003) . In the purified PARP-1 assay used here, the IC 50 value for AG14361 was 2072 nM. NU7026 is a competitive and highly selective inhibitor of DNA-PK, with a 60-fold greater potency against this enzyme than PI 3-K, and inactive against both ATM and ATR (Veuger et al., 2003) . In the purified DNA-PK assay used here, the IC 50 value for NU7026 was 450720 nM. Concentrations of 0.4 mM AG14361 and 10 mM NU7026 were used in all subsequent in vitro and intact cell assays. These concentrations were based on previous data showing that these concentrations completely inhibited purified enzyme activity and caused maximal radiopotentiation and DNA DSB inhibition in cell culture (Veuger et al., 2003) .
Concentrations of enzymes and DNA ends
There are about one million molecules each of PARP-1 and DNA-PK in the cell (Lindahl et al., 1995; Jackson, 1997) . Therefore, in the experimental protocols described here, equimolar concentrations of PARP-1 and the DNA-PK holoenzyme were used (based on their published molecular weights of 116 and B600 kDa, respectively), unless otherwise specified. The ratios of the numbers of DNA oligonucleotide ends to enzyme molecules were also kept constant at B10 : 1. Thus, under the assay conditions used, direct competition of enzyme molecules for DNA ends will have been minimized.
Statistical analyses
All data presented were the mean7standard error (s.e.) of at least three independent experiments. All differences cited in the text were confirmed as significant (P-values p0.05), as evaluated by the two-tailed Student's t-test.
Cell lines and culture
Primary PARP-1 þ / þ and PARP-1 À/À mouse embryonic fibroblasts (MEFs) were a gift from Professor Gilbert de Murcia, É cole Supe´rieure de Biotechnologie de Strasbourg, France. Spontaneously immortalized cell lines were derived from the primary cells, and were used in the experiments here. The Chinese hamster cell lines, V3 (mutated in DNA-PKcs), and V3YAC (V3 transfected with a yeast artificial chromosome (YAC) carrying the complementing human DNA-PKcs gene) were kindly provided by Dr Penny Jeggo, University of Sussex . The Chinese hamster xrs-6 cell line was derived from the CHO-K1 cell line. It lacks functional Ku80 due to a splice site mutation arising from a 13 bp insertion and ensuing frameshift (Singleton et al., 1997) . This cell line was obtained from the European Collection of Cell Cultures, together with the parental CHO-K1 cell line. All cell lines were cultured as monolayers in DMEM medium (supplemented with 10% (v/v) fetal calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin). Glutamine was added at a final concentration of 2 mM. The V3YAC cell line was maintained under antibiotic selection with genticin (Gibco BRL, Paisley, UK) at a final concentration of 500 mg/ml, to ensure retention of the YAC. and/or NU7026 in DMSO were added to the reaction mix such that the final DMSO concentration remained constant at 1% (v/v). Reactions were initiated by the addition of 50 ml containing 100 ng PARP-1 in 15 mM Tris-HCl (pH 8.0), 20 mM MgCl 2 and 0.4 mM DTT. Incubations for 5 min were carried out at 261C in a shaking waterbath. Reactions were terminated by the addition of 25 ml ice-cold TCA (99% w/v TCA, 1% (w/v) Na pyrophosphate). Enzyme activity was quantitated by the incorporation of radiolabelled poly(ADPribose) from [ 32 P]NAD þ into TCA-precipitable counts, estimated by liquid scintillation counting, and expressed as pmol NAD þ incorporated/mg protein. When PARP-1 activity was assayed in the presence of DNA-PK, the enzymes were mixed prior to addition to the reaction mix. Where specified, ATP (50 mM final concentration) was added to the reaction mix. Based on the known molecular weights of the enzymes (116 kDa for PARP-1 and B600 kDa for the DNA-PK holoenzyme), enzymes were added at 1 : 1, 1 : 2 and 1 : 3 molar ratios (see figure legends for details).
Purified DNA-PK assay DNA-PK activity was quantitated by the amount of [ 32 P] from ATP incorporated by phosphorylation of a wt p53 peptide substrate (EPPLSQEAFADLLKK). Standard DNA-PK assays (10 ml) contained 500 ng DNA-PK, 100 ng oligonucleotide, 200 mM peptide, 48 mM Tris-HCl (pH 8.0), 24 mM MgCl 2 and 0.2 mM DTT. AG14361 and/or NU7026 in DMSO were added to the reaction mix such that the final DMSO concentration remained constant at 1% (v/v). Reactions were initiated by the addition of 1 ml 500 mM ATP containing 0.5 mCi [ 32 P]ATP (s.a. 3000 Ci/mmol, Amersham, Bucks.). Each tube was vortexed and incubated for 10 min at 301C. Reactions were terminated by the addition of 10 ml 30% (v/v) acetic acid, and enzyme activity quantitated by spotting onto phosphocellulose paper, washing and subjecting to liquid scintillation counting as described . When DNA-PK activity was assayed in the presence of PARP-1, the enzymes were mixed prior to addition to the reaction mix. Where specified, NAD þ (200 mM final concentration) was added to the reaction mix.
PARP-1 permeabilized cell assay PARP-1 was assayed in permeabilized cells using a modification of the method of Halldorsson et al. (1978) . Briefly, instead of using a hypotonic buffer with cold shock, cells were permeabilized by a 10-min incubation on ice in digitonin (150 mg/ml) before the addition of 9 v of ice-cold isotonic buffer. The subsequent protocol was as described, except that, instead of DNAase 1, the 30 bp double-stranded oligonucleotide was added to the assay at a final concentration of 2.5 mg/ ml, to stimulate PARP-1 activity, and the final concentration of NAD in the reaction mix was 75 mM. As in the purified PARP-1 assay, enzyme activity was quantitated by the incorporation of radiolabelled poly(ADP-ribose) from [ 32 P]NAD þ into TCA-precipitable counts. Results were expressed as pmol NAD þ incorporated/10 6 cells.
DNA strand break assays
DNA DSB levels were measured by neutral filter elution, and DNA SSB levels were measured by alkaline elution (Bradley and Kohn, 1979; Kohn et al., 1981) . The radiolabelling, drug treatment, post-incubation conditions and sample preparation used in these experiments were exactly as described by Boulton et al. (1996) . In all experiments measuring DNA DSB levels, cells were exposed to 75 Gy IR unless otherwise stated. In experiments measuring DNA SSBs, cells were exposed to 6 Gy. Cell cultures were pre-incubated7AG14361 (0.4 mM) and/or NU7026 (10 mM) for 60 min prior to exposure to IR, and the drugs remained in the culture medium during the postincubation periods. Regression analysis of each elution profile was performed to calculate the relative retention, that is, the fraction of sample DNA retained on the filter when 50% of the internal standard has eluted (Fornace and Little, 1977) . Values for cells treated with IR7inhibitor(s) were expressed as a percentage of the values of the unirradiated controls.
